A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
Roswell Park Cancer Institute
University of Washington
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Sumitomo Pharma America, Inc.
Eastern Cooperative Oncology Group
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Vanquish Oncology, Inc.
Dana-Farber Cancer Institute
Pfizer
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
Peking Union Medical College Hospital
Dana-Farber Cancer Institute
University of Iowa
Federation Francophone de Cancerologie Digestive
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Novartis
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)